- Home
- SXC vs ABUS Comparison
SXC vs ABUS Comparison
Compare SXC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXC
- ABUS
- Stock Information
- Founded
- SXC 1960
- ABUS N/A
- Country
- SXC United States
- ABUS United States
- Employees
- SXC N/A
- ABUS N/A
- Industry
- SXC Steel/Iron Ore
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- SXC Industrials
- ABUS Health Care
- Exchange
- SXC Nasdaq
- ABUS Nasdaq
- Market Cap
- SXC 722.8M
- ABUS 725.9M
- IPO Year
- SXC N/A
- ABUS N/A
- Fundamental
- Price
- SXC $12.63
- ABUS $3.46
- Analyst Decision
- SXC Strong Buy
- ABUS Strong Buy
- Analyst Count
- SXC 1
- ABUS 4
- Target Price
- SXC $13.00
- ABUS $5.50
- AVG Volume (30 Days)
- SXC 907.2K
- ABUS 837.4K
- Earning Date
- SXC 10-31-2024
- ABUS 11-06-2024
- Dividend Yield
- SXC 3.77%
- ABUS N/A
- EPS Growth
- SXC 55.48
- ABUS N/A
- EPS
- SXC 1.01
- ABUS N/A
- Revenue
- SXC $1,970,000,000.00
- ABUS $6,742,000.00
- Revenue This Year
- SXC N/A
- ABUS N/A
- Revenue Next Year
- SXC N/A
- ABUS N/A
- P/E Ratio
- SXC $12.42
- ABUS N/A
- Revenue Growth
- SXC N/A
- ABUS N/A
- 52 Week Low
- SXC $7.47
- ABUS $1.79
- 52 Week High
- SXC $12.81
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- SXC 78.64
- ABUS 30.63
- Support Level
- SXC $12.29
- ABUS $3.42
- Resistance Level
- SXC $12.71
- ABUS $3.81
- Average True Range (ATR)
- SXC 0.42
- ABUS 0.16
- MACD
- SXC 0.03
- ABUS -0.04
- Stochastic Oscillator
- SXC 93.75
- ABUS 7.41
About SXC SunCoke Energy Inc.
SunCoke Energy Inc operates as an independent producer of coke in the Americas. The company operates through three segments: Domestic Coke, Brazil Coke, and Logistics. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal producing, and other manufacturing-based customers.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.